*Disseminated on behalf of Medicus Pharma Ltd.
5 Potential Catalysts Pin (Nasdaq: MDCX) To My Watchlist's Top Spot (Low Float Idea)
July 6th Greetings, Friend!
In the fast-paced life sciences sector, a few companies are gaining notice for developing innovative therapies targeting major unmet medical needs.
One little-known company's subsidiary is advancing a dissolvable microneedle patch to deliver chemotherapy directly to skin tumors, aiming to change treatment for basal cell carcinoma as we know it.
This non-invasive approach is in clinical trials in the U.S. and UAE and could offer a less invasive, more patient-friendly alternative to surgery or systemic drugs.
The company is also expanding through acquisitions, including a late-stage UK biotech focused on advanced prostate therapies, signaling a broader ambition in areas with high unmet needs.
Factor in a low float (under 3Mn shares), two analyst targets indicating significant upside potential, and a major acquisition proceeding forward, this Nasdaq profile could soon be attracting serious attention.
Consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar.
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents.
Complete Company Details - Medicus Pharma Ltd. (Nasdaq: MDCX)
Focus: Accelerating clinical development of novel therapeutics across multiple countries and continents.
Specialty: Moving innovative therapies quickly through clinical stages.
About SkinJect (Medicus Pharma's Wholly Owned Subsidiary)
Product: Patented dissolvable microneedle patch (D-MNA) for non-melanoma skin cancer, especially basal cell carcinoma.
Mechanism: Delivers doxorubicin directly to tumor via transdermal microneedles, aiming to replace invasive Mohs surgery with a painless, office-based treatment.
Rights: Exclusive global development and commercialization rights from University of Pittsburgh and Carnegie Mellon since 2016.
Clinical Progress
Phase 1 (2021): Demonstrated safety, tolerability, and some complete responses.
Phase 2: IND submitted to FDA in January 2024; patient recruitment began August 2024 at 9 US sites.
Interim analysis (March 2025): Over 60% complete clinical response; trial expanded from 60 to 90 patients.
SkinJect Value Proposition
Innovation: Patented, non-invasive microneedle patch for direct drug delivery to skin tumors.
Market: BCC is the most common cancer globally; North American market projected at $15Bn by 2030.
Clinical Results: Positive safety and efficacy data in early trials, with ongoing Phase 2 showing promise.
Leadership: Experienced management and board with oncology and drug development expertise.
Medicus Pharma (Nasdaq: MDCX) is positioned to impact standards of care in both human and veterinary medicine, with ongoing clinical and regulatory milestones.
Find Sources Here: MDCX Presentation. MDCX Website. -----
5 Potential Catalysts Could Provide (Nasdaq: MDCX) With A Breakout Spark!
#1. A Low Float Scenario: With roughly 2.34Mn shares in its float, volatility potential could be heightened at the drop of a hat.
#2. Two Analyst Targets Suggest MDCX May Be Undervalued.
Take a look at these two targets found over at MarketBeat: |
0 Response to "5 Potential Catalysts Pin (Nasdaq: MDCX) To My Watchlist's Top Spot (Low Float Idea)"
Post a Comment